



Universiteit
Leiden
The Netherlands

Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: implications for shared decision making.

Post, C.C.B.; Mens, J.W.M.; Haverkort, M.A.D.; Koppe, F.; Jurgensliemk-Schulz, I.M.; Snyers, A.; ... ; Creutzberg, C.L.

Citation

Post, C. C. B., Mens, J. W. M., Haverkort, M. A. D., Koppe, F., Jurgensliemk-Schulz, I. M., Snyers, A., ... Creutzberg, C. L. (2021). Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: implications for shared decision making. *Gynecologic Oncology*, 161(3), 727-733. doi:10.1016/j.ygyno.2021.03.004

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3276102>

Note: To cite this publication please use the final published version (if applicable).



Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Cathalijne C.B. Post ^{a,*}, Jan Willem M. Mens ^b, Marie A.D. Haverkort ^c, Friederike Koppe ^d, Ina M. Jürgenliemk-Schulz ^e, An Snyers ^f, Ellen M.A. Roeloffzen ^g, Eva E. Schaake ^h, Annerie Slot ⁱ, Tanja C. Stam ^j, Jannet C. Beukema ^k, Hetty A. van den Berg ^l, Ludy C.H.W. Lutgens ^m, Hans W. Nijman ⁿ, Cornelis D. de Kroon ^o, Judith R. Kroep ^p, Anne M. Stiggelbout ^q, Carien L. Creutzberg ^a

^a Department of radiation oncology, Leiden University Medical Centre, Leiden, the Netherlands

^b Department of radiation oncology, Erasmus MC, Rotterdam, the Netherlands

^c Department of radiation oncology, Radiotherapiegroep, Arnhem, the Netherlands

^d Department of radiation oncology, Institute Verbeeten, Tilburg, the Netherlands

^e Department of radiation oncology, University Medical Centre Utrecht, Utrecht, the Netherlands

^f Department of radiation oncology, Radboud University Medical Centre, Nijmegen, the Netherlands

^g Department of radiation oncology, Isala, Zwolle, the Netherlands

^h Department of radiation oncology, National Cancer Institute, Amsterdam, the Netherlands

ⁱ Department of radiation oncology, Radiotherapeutic Institute Friesland, Leeuwarden, the Netherlands

^j Department of radiation oncology, Haaglanden Medical Centre, the Hague, the Netherlands

^k Department of radiation oncology, University Medical Centre Groningen, Groningen, the Netherlands

^l Department of radiation oncology, Catharina Hospital, Eindhoven, the Netherlands

^m Department of radiation oncology, Maastricht, Maastricht, the Netherlands

ⁿ Department of obstetrics and gynaecology, University Medical Centre Groningen, Groningen, the Netherlands

^o Department of obstetrics and gynaecology, Leiden University Medical Centre, Leiden, the Netherlands

^p Department of medical oncology, Leiden University Medical Centre, Leiden, the Netherlands

^q Department of biomedical data sciences, Leiden University Medical Centre, Leiden, the Netherlands

HIGHLIGHTS

- Desired benefit to choose adjuvant chemotherapy was assessed in endometrial cancer.
- Desired benefit varied considerably among and between patients and clinicians.
- Patients desired higher survival benefit than clinicians to choose chemoradiotherapy.
- Survival benefit and long-term symptoms are most important in decision making.
- Patient preferences are strongly influenced by treatment history.

ARTICLE INFO

Article history:

Received 25 January 2021

Accepted 2 March 2021

Available online 10 March 2021

Keywords:

Endometrial cancer

Patient preferences

Clinician preferences

Adjuvant chemotherapy

Chemoradiotherapy

Decision-making

ABSTRACT

Background. Decision making regarding adjuvant therapy for high-risk endometrial cancer is complex. The aim of this study was to determine patients' and clinicians' minimally desired survival benefit to choose chemoradiotherapy over radiotherapy alone. Moreover, influencing factors and importance of positive and negative treatment effects (i.e. attribute) were investigated.

Methods. Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy and multidisciplinary gynaecologic oncology clinicians completed a trade-off questionnaire based on PORTEC-3 trial data.

Results. In total, 171 patients and 63 clinicians completed the questionnaire. Median minimally desired benefit to make chemoradiotherapy worthwhile was significantly higher for patients versus clinicians (10% vs 5%, $p = 0.02$). Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87–0.97]; $p = 0.003$) with comorbidity (OR 0.34 [95%CI 0.12–0.89]; $p = 0.035$) had lower preference for chemoradiotherapy, while patients with better numeracy skills (OR 1.2 [95%CI 1.05–1.36], $p = 0.011$) and chemoradiotherapy history (OR 25.0 [95%CI 8.8–91.7]; $p < 0.001$) had higher preference for chemoradiotherapy.

* Corresponding author at: Leiden University Medical Centre, Street address: Albinusdreef 2, 2333 ZA Leiden, P.O. Box 9600, 2300, RC, Leiden, the Netherlands.
E-mail address: c.c.b.post@lumc.nl (C.C.B. Post).

Conclusions. There is a considerable difference in minimally desired survival benefit of chemoradiotherapy in high-risk endometrial cancer among and between patients and clinicians. Overall, endometrial cancer patients needed higher benefits than clinicians before preferring chemoradiotherapy.

© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Endometrial cancer is the most common gynaecological malignancy in developed countries. Although most women with endometrial cancer are diagnosed at early stage of disease, 15–20% are diagnosed with high-risk disease with increased incidence of recurrence and cancer-related death. The PORTEC-3 trial investigated the treatment effect of combined adjuvant pelvic radiotherapy and chemotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. The updated survival analysis showed a 5-year overall survival (OS) benefit of 5% (81% vs 76%, HR 0.70, $p = 0.034$) and failure-free survival benefit of 7% (76% vs 69%, HR 0.70, $p = 0.016$) with chemoradiotherapy as compared to radiotherapy alone, with the greatest benefit of 10% or more observed in women with serous cancers and those with stage III disease [1]. Toxicity is most frequent and severe during treatment, but the lower grade toxicities, which may have long-term impact, should not be neglected. Pelvic radiotherapy is associated with higher risks of long-term gastro-intestinal and genitourinary symptoms, with impact on physical and role functioning [2,3]. Adding chemotherapy leads to additional symptoms that may persist (e.g. persisting tingling or numbness of hands or feet reported by 25% of the patients at 3 and 5 years after treatment, and a small deterioration in physical and role functioning during the first 3 years after treatment) [4]. Weighing these pros and cons reflects the complexity of shared decision-making on adjuvant treatment for patients with high-risk endometrial cancer.

The current analysis was initiated to investigate preferences of women with high-risk endometrial cancer and multidisciplinary clinicians. The actual differences in survival and symptoms were presented, in order to determine which benefit exceeded the risks sufficiently to consider the addition of chemotherapy to radiotherapy worthwhile in women with high-risk endometrial cancer. In addition, factors influencing the decision and the importance assigned to the major positive and negative treatment outcomes were investigated.

2. Participants and methods

2.1. Study population and procedures

For the patient study, patients with high-risk endometrial cancer were enrolled in 12 radiation oncology centres across the Netherlands. Selection criteria were: surgery with curative intent with adjuvant pelvic radiotherapy with or without chemotherapy; treated after 2014; alive without recurrent disease reported until last follow-up; no other cancer; able to read Dutch. Because of the pragmatic nature of the study and the fact that the indication of adjuvant pelvic radiotherapy is limited to endometrial cancer with high-risk features we used diagnosis and treatment codes for selecting patients from the hospital databases. Patients were approached via their treating radiation oncologist by letter. Patients were asked to fill out a self-administered web-based questionnaire. On request, a paper version was available. An anonymised approach without linked patient report data was used, therefore no reminders could be sent. We pilot-tested the questionnaire in a sample with varied medical history across the Netherlands.

For the clinician study, we approached multidisciplinary gynaecologic oncology clinicians (including radiation oncologists, gynaecologic oncologists and medical oncologists) via the Dutch Gynaecologic Oncology Group. Clinicians were approached via email with a link to the web-based questionnaire. After two weeks clinicians received a

reminder. Question validation was enabled in the web-based questionnaire to prevent missing values. The Medical Ethics Committee of Leiden University Medical Centre approved the study.

2.2. Measures

For the patient study, clinical factors (cancer treatment history and any comorbidities influencing daily life) and sociodemographic factors, health literacy [5] and numeracy [6], treatment preferences and attribute importance ratings were assessed (Appendix A1 displays the health literacy and numeracy questions). For the clinician study, sociodemographic factors, affiliation and main specialty, treatment preferences and attribute importance ratings were assessed.

Participants' minimally desired 5-year overall survival benefit (MDSB) from chemoradiotherapy as compared to radiotherapy alone was assessed using the treatment trade-off method [7]. Patients and clinicians were asked to imagine that they had recently been diagnosed with high-risk endometrial cancer and that their clinician offered them two treatment strategies. We made explicit that the situation was hypothetical and did not refer to their individual situation. Based on known data from the quality of life analysis of the PORTEC-3 trial, an overview with the most frequent symptoms and deterioration in functioning was presented (available in Appendix A2). The importance assigned to every treatment outcome (attribute) was rated using a 4-point Likert-type response scale. Subsequently, participants were asked what treatment option they preferred at a 5% benefit of additional chemotherapy. If they chose radiotherapy alone, the survival benefit with addition of chemotherapy varied with 5% increments to a maximum benefit of 25% over the baseline of 75% until they switched their preference. When participants had chosen chemoradiotherapy at 5% or 10% survival benefit, they were asked for their MDSB (multiple choice question ranging between 1 and 5% or 6 and 10% respectively).

2.3. Statistical analysis

Empty returned questionnaires, those with information on characteristics only, and those with inconsistent answers among the trade-off questions were excluded for analysis as displayed in Fig. 1. The analysis was primarily descriptive. Categorical variables were compared using Fisher's exact test or chi-square test. Continuous and ordinal variables were compared using Mann-Whitney *U* test or Kruskal-Wallis test. The following groups were compared: (A) patients versus clinicians, (B) patients previously treated with adjuvant radiotherapy alone versus chemoradiotherapy, (C) the three clinician specialties.

Univariable and multivariable logistic regression with likelihood-based backward selection were performed to identify predictors for chemoradiotherapy preference at a 5% survival benefit.

A two-sided p -value ≤ 0.05 was considered statistically significant for the treatment trade-off and logistic regression. For comparison of attribute importance ratings, a two-sided p -value ≤ 0.01 was considered statistically significant and ≤ 0.05 was considered a trend to guard against false-positive results due to multiple testing. Statistical analyses were done with R version 3.6.1.




Fig. 1. Flowchart.

3. Results

In total, 453 eligible patients were approached. Of these patients, 205 (45%) started the questionnaire, of which 171 (83%) were evaluable (131 online (77%) and 40 paper (23%); Fig. 1). Among the 106 clinicians approached, 63 (59%; 21/39 radiation oncologists, 34/54 gynaecologic oncologists, and 8/13 medical oncologists) completed the online questionnaire. Table 1 shows the baseline characteristics for both patients and clinicians. Median Subjective Numeracy Scale score was 14 [IQR 11–16] on a scale from 3 to 18 with larger scores indicating a higher subjective rating of numeracy. Median literacy score was 6 [IQR 5–7] on a scale from 0 to 12 with higher scores reflecting greater problems with reading.

3.1. Treatment preference and minimally desired survival benefit

At a 5% survival benefit, 69 (40%) of the patients and 41 (65%) of the clinicians preferred chemoradiotherapy over radiotherapy alone ($p = 0.001$). In Table 2 the MDSB ratings are listed. Fig. 2 shows the cumulative proportion of participants preferring chemoradiotherapy according to MDSB. Overall, the median MDSB for preferring chemoradiotherapy was significantly higher for patients than for clinicians (10% vs 5%, $p = 0.024$). Patients who had received chemoradiotherapy had a significantly lower MDSB than patients who had received radiotherapy alone (2% vs 10%, $p < 0.001$). There was no significant difference between the clinician specialties ($p = 0.46$).

3.2. Attribute importance

Fig. 3 shows the distribution of importance assigned to each attribute by patients and clinicians. Survival benefit was judged as the most important attribute, followed by the long-term symptoms (i.e. '25% with persistent tingling/numbness', and 'small decline in physical functioning'), both by patients and clinicians. There was a trend for patients judging moderate deterioration in physical functioning during treatment more important ($p = 0.025$) and persistent tingling/numbness less important ($p = 0.027$) than clinicians. The treatment duration was judged as least important, especially by clinicians (judged as not important by 30% of patients vs 43% of clinicians, $p < 0.001$). Patients considered diarrhoea ('36% during treatment for both treatment

Table 1
Participant characteristics.

Patients	n = 171
Age, years (median [IQR])	67 [60–72]
Marital status (%)	
Married/Living together	100 (58.5)
Partner, living alone	6 (3.5)
No partner/widow	65 (38.0)
Having children = Yes (%)	121 (70.8)
Educational level (%)	
Low	69 (40.4)
Intermediate	49 (28.7)
High	50 (29.2)
Other	3 (1.8)
Main daily activity (%)	
Paid/unpaid job	54 (31.6)
Leisure and IADLS	117 (68.4)
Comorbidity = Yes (%)	123 (71.9)
Received radiotherapy (%)	
EBRT	95 (55.6)
EBRT + VBT	69 (40.4)
VBT	5 (2.9)
Unknown	2 (1.2)
Chemotherapy = Yes (%)	42 (24.6)
Time since diagnosis in, years (median [IQR])	3 [2–5]
Clinicians	n = 63
Age, years (median [IQR])	50 [43–56]
Sex (%)	
Male	16 (25.4)
Female	47 (74.6)
Specialty (%)	
Radiation oncology	21 (33.3)
Gynaecologic oncology	34 (54.0)
Medical oncology	8 (12.7)
Current institution (%)	
General	28 (44.4)
Academic	25 (39.7)
Categorical	10 (15.9)
Number of EC patients per month (median [IQR])	4 [2–5]

Education level: low = elementary school, completed lower general secondary education/vocational training; intermediate: higher secondary educational/vocational training; high = higher professional education, university, doctor.
EBRT = External beam radiotherapy; EC = Endometrial cancer; IADLS: Instrumental Activities of Daily Living; VBT = vaginal brachytherapy.

Table 2
Minimally desired survival benefit (MDSB) from chemoradiotherapy.

	MDSB	Percentile				NA	p
		25th	75th	5th	95th		
Patients (n = 171)	10	4	20	1	infin.	7	0.024*
Received Pelvic Radiotherapy (n = 129)	15	5	25	1	infin.	7	<0.001†
Received Chemoradiotherapy (n = 42)	2	1	5	0	15		
Clinicians (n = 63)	5	3	10	2	25	1	0.46†
Radiation oncologists (n = 21)	5	4	10	2	25	1	
Gynaecologic oncologists (n = 34)	5	3	10	2	20		
Medical oncologists (n = 8)	4	3	5	3	10		

p values less than or equal to 0.05 were deemed significant. *Between group comparison: patients versus clinicians; †Within group comparison.

groups'; $p = 0.001$) and social functioning during treatment ('moderate deterioration'; $p = 0.003$) more important in their decision than clinicians.

Patients who had received chemoradiotherapy judged treatment duration less important than those who had received radiotherapy

alone (judged as not important by 55% [CTRT] vs 22% [RT], $p < 0.001$), as well as hair loss during treatment (36% vs 16%, $p = 0.003$). In addition, there was a trend for several other negative attributes to be judged less important by patients who had received chemoradiotherapy (Appendix Fig. B1). There were no statistically significant differences in attribute importance between the three clinician specialties. However, there was a trend for different ratings of short-term fatigue and quality of life, and short- and long-term functioning importance, with radiation oncologists rating these attributes of higher importance than other specialists ($p < 0.05$; Appendix Fig. B2).

3.3. Factors influencing treatment preference

Multivariable logistic regression showed that patients with an older age (OR 0.92 [95% CI 0.87–0.97]; $p = 0.003$) and comorbidity (OR 0.34 [95% CI 0.12–0.89]; $p = 0.035$) were less likely to prefer chemoradiotherapy, while those with a higher subjective numeracy score (OR 1.2 [95% CI 1.05–1.36], $p = 0.011$) and a chemoradiotherapy history (OR 25.0 [95% CI 8.8–91.7]; $p < 0.001$) were more likely to prefer chemoradiotherapy over radiotherapy alone (Table 3). For clinicians, none of baseline variables entered in the multivariable logistic regression model were statistically significant predictors (data not shown).

4. Discussion

This patient preference study for high-risk endometrial cancer showed that patients desired higher survival benefits than clinicians before preferring adjuvant chemoradiotherapy over radiotherapy alone. The minimally desired survival benefit varied considerably among both patients and clinicians. Patients' preferences were strongly influenced by treatment history. In addition, younger age, having no comorbidities and higher subjective rating of numeracy were predictors of the preference for chemoradiotherapy. Survival benefit was judged to be the most important attribute in decision making by both patients and clinicians, followed by the risk of developing long-term symptoms (i.e. neuropathy and impaired physical functioning).

Patients had a median MDSB of 10% over the baseline 5-year survival rate of 75% with radiotherapy alone, while clinicians had a median MDSB of 5% to make adjuvant chemoradiotherapy worthwhile. It was unexpected that we found different results compared to those of the previous patient preference study related to the PORTEC-3 trial. The ANZGOG sub-study among 83 high-risk endometrial cancer patients recruited to the PORTEC-3 trial found that patients, compared to clinicians, desired lower benefits to make chemoradiotherapy worthwhile (4% vs 10% over a 5-year survival rate of 65%) [8]. Having encountered the symptoms and adverse events of patients, but particularly knowing the results of the PORTEC-3 trial (5% benefit) may have made the clinicians in our study less reluctant in accepting chemotherapy for a small benefit. The relatively low survival benefit desired among patients in the ANZGOG sub-study may be explained by the selection of patients who had decided to take part in the PORTEC-3 trial and thus were likely to accept chemotherapy for an uncertain benefit. Meanwhile, patient preferences in our study were influenced by treatment history, and most patients (75%) did not receive chemotherapy.

The variability of MDSB was high, although the range among clinicians was slightly narrower than among patients. This high variability in preferences has been reported by others as well [8–10]. Younger age, having no comorbidity and better numeracy skills were predictive for preferring chemoradiotherapy in our study, while most studies report a lack of predictors. Nevertheless, individual treatment preferences remain hard to predict from baseline characteristics, and are most likely influenced by a complex of experiences, values and attitudes. Treatment preferences are clearly influenced by actual treatment received. Many studies have reported that patients who are about to undergo treatment or have experienced a treatment generally adapt to their decision by having stronger preference for that treatment [9,11,12]. This is a




Fig. 2. Cumulative proportion of participants preferring chemoradiotherapy over radiotherapy alone according to minimally desired survival benefit by patients versus clinicians (A) and their subgroups (B). Baseline 5-year survival rate with radiotherapy alone is 75%. The maximum survival benefit is 25% corresponding to a 5-year survival rate of 100%. Numbers do not add up to 1.00 because of those declining chemoradiotherapy irrespective of any survival benefit. CTRT = Chemoradiotherapy. RT = Radiotherapy.




Fig. 3. Attribute importance ratings in the decision between chemoradiotherapy and radiotherapy alone after reading the trade-off overview with a 5% survival benefit. Pt = Patients. CI = Clinicians. *p value less than or equal to 0.01 shows significance; **p value less than or equal to 0.05 shows a trend.

known psychologic process to make preferences agree with the preceding decision called cognitive dissonance reduction or cognitive justification. In the shared decision making process, it may be helpful to explore the patient's prior experience with the treatments considered, e.g. in close family members, and discuss the potential bias this may have caused.

We did not find a significant difference in MDSB between clinicians from different specialties. Previous research reported that clinicians generally need less benefit from the treatment of their own specialty [9,13,14]. The fact that this was not found in our study may be explained by the small number of medical oncologist, multidisciplinary treatment approach in current practice and knowledge of the PORTEC-3 trial results.

The most important attribute in decision making, for both patients and clinicians, was survival benefit. This has been reported in several cancer preference studies [15,16]. However, thorough evaluation of multiple attributes, especially with distinction of short-term and long-term impairments, is novel. Some studies emphasised the importance of quality of life in general, but without detailed attributes [16,17]. We found that the risk of developing long-term symptoms (i.e. neuropathy and impaired physical functioning) is of high importance to patients. While treatment duration was considered the least important attribute, all short-term symptoms and impairments were of intermediate importance.

There were clear strengths to our study. First, many patients across our entire country participated to represent the Dutch high-risk

endometrial cancer population. This, together with the relative large sample size allowed subgroup analysis and multivariable logistic regression. Second, the presented information on survival and long-term symptoms were based on the actual data of the randomised PORTEC-3 trial, ensuring a reliable representation of clinical practice. In addition, the novelty of our study was enhanced by allowing a thorough analysis of attribute importance. Third, the web-based questionnaire design prevented interviewer introduced bias, facilitated response, allowed direct comparison between patients and clinicians, and provided complete data.

The main limitation of our study was the inability to include patients at the moment they were actually facing the treatment decision. Our results were clearly influenced by the preceding treatment. Selecting only disease-free patients may have reinforced this influence. Generally, patients without recurrence are more satisfied with care than patients with recurrence [18]. In addition, we did not have details on the patient's persistent symptoms, which may be influencing preference as well. Lastly, response bias may have occurred. Due to the non-random sample and the lack of information on patients who did not complete the questionnaire, we are unable to correct for this potential bias.

Clinical implications of this study are knowledge of the variability of preferences among endometrial cancer patients facing the treatment decision for adjuvant chemoradiotherapy, and of the differences between clinicians and patients. Therefore, detailed discussion about the benefits and harms are necessary to ensure their decisions are well

Table 3
Predictors of preference for chemoradiotherapy at a 5% survival benefit among patients.

	Univariable logistic regression				Multivariable logistic regression			
	OR	Lower 95% CI	Upper 95% CI	p	OR	Lower 95% CI	Upper 95% CI	p
Age	0.92	0.88	0.96	<0.001	0.92	0.87	0.97	0.003
Comorbidity (Yes vs No)	0.35	0.15	0.73	0.007	0.34	0.12	0.89	0.035
Received CRT (Yes vs No)	26.3	9.59	93.1	<0.001	27.5	9.22	106	<0.001
Subjective Numeracy Scale	1.13	1.03	1.24	0.015	1.18	1.05	1.36	0.011

p values less than or equal to 0.05 were deemed significant. CRT = Chemoradiotherapy. IADLS = Instrumental Activities of Daily Living. OR = Odds ratio for chemoradiotherapy preference in the decision between chemoradiotherapy and radiotherapy alone after seeing the trade-off overview with a 5% survival benefit. 95% CI = 95% Confidence interval.

informed and aligned with their personal values, attitudes and priorities, and not unduly influenced by clinician preferences. Clinicians tend to underestimate patients preference for less toxic treatments [19,20]. As reinforced by this study, it is important to realise that patients might not be as willing to undergo chemotherapy as clinicians themselves. In addition, it would be important to realise that patients highly value clinicians' recommendations and that recommendations may lead people to make decisions that ultimately go against what they would otherwise prefer [21]. With the actual 5% overall survival difference in the PORTEC-3 trial [1], only 40% of the patients and 63% of clinicians would prefer adjuvant chemoradiotherapy over radiotherapy alone. Based on a survival benefit of 10% or more, adjuvant chemoradiotherapy is only advised for women with stage 3 disease and those with serous or p53 abnormal endometrial cancer [1,22]. Our study showed that with this benefit, 57% of the patients and 84% of the clinicians would prefer adjuvant chemoradiotherapy.

Our results on attribute importance can guide patient information. It is important to point out the possibility of long-term symptoms. Patients should be informed about the expected toxicity due to standard adjuvant pelvic radiotherapy before making a decision, even if the risk is equal when adding adjuvant chemotherapy (e.g. 36% risk of diarrhoea). Although individually not significant, patients rated most negative attributes more important than clinicians. Meanwhile, clinicians seem to rate long-term tingling/numbness higher than patients. Clinicians may imagine the accompanied burden they have seen in practice resulting in higher attribute values, while the terms 'tingling', 'numbness' or 'neuropathy' might be abstract for patients without knowledge or experience. Therefore, it is important that clinicians ask about hobbies and other social activities that might be impacted and give practical examples to make it more imaginable.

In conclusion, our results showed considerable differences in minimally desired survival benefit to make adjuvant chemoradiotherapy in high-risk endometrial cancer worthwhile, both among and between patients and clinicians. Overall, endometrial cancer patients desired higher survival benefits than clinicians before preferring chemoradiotherapy.

Authors' contributions

Conception, design and development of methodology: CCBP, AMC, CLC. Patient inclusion: CCBP, JWMM, MADH, FK, IMJS, AS, EMAR, EES, AS, TCS, JCB, HAB, LCHWL, CLC. Data analysis and interpretation: CCBP, AMC, CLC. Writing, review and/or revision of the paper: CCBP, JWMM, MADH, FK, IMJS, AS, EMAR, EES, AS, TCS, JCB, HAB, LCHWL, HWN, CDK, JRK, AMS, CLC. All authors read and approved the final paper.

Ethical approval and consent to participate

The Medical Ethics Committee of Leiden University Medical Centre reviewed and approved the current study. The study was performed in accordance with the Declaration of Helsinki, and informed consent was obtained from each patient. For the online questionnaire patients consented before starting the questionnaire. For the paper version participants consented by completing and returning the questionnaire.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interest

The authors declare no competing interest.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

We thank all participating patients and clinicians for their efforts. We also thank all participating centres. Furthermore, we thank Corine de Jong and Anne-Sophie van den Heerik for sending out paper questionnaires.

Appendix A. Supplementary methods

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ygyno.2021.03.004>.

References

- [1] S.M. de Boer, M.E. Powell, L. Mileschkin, D. Katsaros, P. Bessette, C. Haie-Meder, et al., Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial, *Lancet Oncol.* (2019) [https://doi.org/10.1016/s1470-2045\(19\)30395-x](https://doi.org/10.1016/s1470-2045(19)30395-x).
- [2] R.A. Nout, L.V. Poll-Franse, M.L.M. Lybeert, C.C. Wárlám-Rodenhuis, J.J. Jobsen, J.W.M. Mens, et al., Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial, *J. Clin. Oncol.* 29 (2011) 1692–1700.
- [3] S.M. De Boer, R.A. Nout, I.M. Jurgensliemk-Schulz, J.J. Jobsen, L.C.H.W. Lutgens, E.M. Van Der Steen-Banasik, et al., Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial, *Int. J. Radiat. Oncol. Biol. Phys.* 93 (2015) 797–809.
- [4] C.C.B. Post, S.M. de Boer, M.E. Powell, L. Mileschkin, D. Katsaros, P. Bessette, et al., Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial, *Int. J. Radiat. Oncol. Biol. Phys.* 109 (2020) 975–986.
- [5] L.D. Chew, J.M. Griffin, M.R. Partin, S. Noorbaloochi, J.P. Grill, A. Snyder, et al., Validation of screening questions for limited health literacy in a large VA outpatient population, *J. Gen. Intern. Med.* 23 (2008) 561–566.
- [6] C.D. McNaughton, K.L. Cavanaugh, S. Kripalani, R.L. Rothman, K.A. Wallston, Validation of a short, 3-item version of the subjective numeracy scale, *Med. Decis. Mak.* 35 (2015) 932–936.
- [7] A.M. Stiggelbout, J.C.J.M. de Haes, Patient preference for cancer therapy: an overview of measurement approaches, *J. Clin. Oncol.* 19 (2001) 220–230.
- [8] On behalf of the ANZGOG and PORTEC Group, P. Blinman, L. Mileschkin, P. Khaw, G. Goss, C. Johnson, et al., Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, *Br. J. Cancer* 115 (2016) 1179–1185.
- [9] M. Kunneman, A.H. Pieterse, A.M. Stiggelbout, R.A. Nout, M. Kamps, L.C. Lutgens, et al., Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians, *Br. J. Cancer* 111 (2014) 674–679.
- [10] V.C. Hamelinck, E. Bastiaannet, A.H. Pieterse, I. Jannink, C.J.H. van de Velde, G.-J. Liefers, et al., Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review, *Cancer Treat. Rev.* 40 (2014) 1005–1018.
- [11] S.J. Jansen, J. Kievit, M.A. Nooij, J.C. de Haes, I.M. Overpelt, H. van Slooten, et al., Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? *Br. J. Cancer* 84 (2001) 1577–1585.
- [12] S.J. Jansen, J. Kievit, M.A. Nooij, A.M. Stiggelbout, Stability of patients' preferences for chemotherapy: the impact of experience, *Med. Decis. Mak.* 21 (2001) 295–306.
- [13] F.J. Fowler Jr., M. McNaughton Collins, P.C. Albertsen, A. Zietman, D.B. Elliott, M.J. Barry, Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer, *JAMA* 283 (2000) 3217–3222.
- [14] A.M. Stiggelbout, J.C. de Haes, C.J. van de Velde, Adjuvant chemotherapy in node negative breast cancer: patterns of use and oncologists' preferences, *Ann. Oncol.* 11 (2000) 631–633.
- [15] A. Livingstone, A. Agarwal, M.R. Stockler, A.M. Menzies, K. Howard, R.L. Morton, Preferences for immunotherapy in melanoma: a systematic review, *Ann. Surg. Oncol.* 27 (2020) 571–584.
- [16] V. Valenti, J. Ramos, C. Perez, L. Capdevila, I. Ruiz, L. Tikhomirova, et al., Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer, *Clin. Transl. Oncol.* 22 (2020) 935–942.
- [17] C.G. Koedoot, R.J. de Haan, A.M. Stiggelbout, P.F. Stalmeier, A. de Graeff, P.J. Bakker, et al., Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice, *Br. J. Cancer* 89 (2003) 2219–2226.
- [18] B.H. de Rooij, H. Ikiz, D. Boll, J.M.A. Pijnenborg, B.M. Pijlman, R. Kruitwagen, et al., Recurrent Cancer is associated with dissatisfaction with care—a longitudinal analysis among ovarian and endometrial cancer patients, *Int. J. Gynecol. Cancer* 28 (2018) 614–622.

- [19] J.J. van Tol-Geerdink, P.F. Stalmeier, E.N. van Lin, E.C. Schimmel, H. Huizenga, W.A. van Daal, et al., Do patients with localized prostate cancer treatment really want more aggressive treatment? *J. Clin. Oncol.* 24 (2006) 4581–4586.
- [20] P.F. Stalmeier, J.J. van Tol-Geerdink, E.N. van Lin, E. Schimmel, H. Huizenga, W.A. van Daal, et al., Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy, *J. Clin. Oncol.* 25 (2007) 3096–3100.
- [21] A.D. Gurmankin, J. Baron, J.C. Hershey, P.A. Ubel, The role of physicians' recommendations in medical treatment decisions, *Med. Decis. Mak.* 22 (2016) 262–271.
- [22] A. Leon-Castillo, S.M. de Boer, M.E. Powell, L.R. Mileshekin, H.J. Mackay, A. Leary, et al., Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy, *J. Clin. Oncol.* (2020)<https://doi.org/10.1200/JCO.20.00549> JCO2000549.